Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

• ClinicalTrials.gov Identifier: NCT00335244
• Recruitment Status: Completed
• First Posted: June 9, 2006
• Last Update Posted: February 2, 2015
• Sponsor: Asklepion Pharmaceuticals, LLC
• Collaborator: Vanderbilt University
• Information provided by (Responsible Party): Asklepion Pharmaceuticals, LLC

Study Description

Brief Summary:

This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery. Participants will be randomly assigned to either L-citrulline or a placebo (a substance that has no medicine in it).

Citrulline is a protein building block in the body that can convert into another substance, nitric oxide (NO), which controls blood pressure in the lungs. Increased blood pressure in the lungs can be an important surgical problem; it may also lead to problems following surgery, such as severe high blood pressure in the lungs (pulmonary hypertension), increased time spent on a breathing machine, and a longer stay in the intensive care unit (ICU). The hypothesis of this study is that perioperative supplementation with intravenous citrulline will increase plasma citrulline, arginine and NO metabolites and prevent elevations in the postoperative PVT leading to a decrease in the duration of postoperative invasive mechanical ventilation.

Condition or disease	Intervention/treatment	Phase
Heart Defects, Congenital; Hypertension, Pulmonary	Drug: L-citrulline; Drug: Placebo of intravenous L-citrulline	Phase 3

Detailed Description:

Increased pulmonary vascular tone (PVT) can complicate the postoperative course of the following five surgical procedures for congenital heart defects: 1) unrestrictive ventricular septal defect (VSD) repair; 2) atrioventricular septal (AVSD) repair; 3) arterial switch procedure for transposition of the great arteries (TGA); 4) bidirectional Glenn shunt procedure; and 5) Fontan procedure for single ventricle lesions. PVT is partially controlled by NO. Arginine, the precursor to NO, is a product of the urea cycle. Preliminary data have been presented regarding 169 infants and children who have undergone one of six previous surgical procedures. It was found that urea cycle function and plasma arginine levels were significantly decreased in all participants. Furthermore, participants with increased PVT had significantly lower arginine levels compared to participants with normal PVT. Finally, a genetic single nucleotide polymorphism (SNP) in the rate limiting urea cycle enzyme (carbamyl phosphate synthetase I [CPSl T1405N]) appeared to affect postoperative plasma arginine levels and PVT. The hypothesis is that genetic polymorphisms in the rate limiting urea cycle enzyme CPSl, and other important enzymes in the urea cycle, influence the availability of NO precursors. It is further hypothesized that perioperative enhancement of urea cycle function with the key urea cycle intermediate (citrulline) will increase plasma arginine and NO metabolites and prevent elevations in PVT.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 77 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: A Phase III Single-Blind, Randomized, Placebo Controlled, Clinical Trial to Determine the Safety and Efficacy of Intravenous L-Citrulline Versus Placebo in Children Undergoing Cardiopulmonary Bypass
• Study Start Date: May 2006
• Actual Primary Completion Date: December 2009
• Actual Study Completion Date: December 2009

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Intravenous L-citrulline	Drug: L-citrulline; 150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
Placebo Comparator: 2; Placebo of intravenous L-citrulline	Drug: Placebo of intravenous L-citrulline; Placebo of intravenous L-citrulline

Outcome Measures

Primary Outcome Measures :

1. Duration of postoperative mechanical ventilation in hours compared between treatment groups. [ Time Frame: Measured in hours from the end of surgery until extubation ]

Secondary Outcome Measures :

1. Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours [ Time Frame: Measured in hours from the end of surgery until extubation ]
2. Postoperative intravenous inotrope score [ Time Frame: Measured at 48 hours ]
3. Length and volume of chest tube drainage [ Time Frame: Measured in hours from the end of surgery until removal of chest tubes ]
4. Length of ICU stay [ Time Frame: Measured in hours from the end of surgery to discharge from ICU ]
5. Length of hospitalization [ Time Frame: Measured from the day of surgery until discharge from hospital ]
6. Survival [ Time Frame: Measured at 30 days post surgical repair ]

Eligibility Criteria

• Ages Eligible for Study: up to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Undergoing cardiopulmonary bypass surgery with 1 of the following 5 procedures:

  1. AVSD repair
  2. VSD repair
  3. Bidirectional Glenn
  4. Modified Fontan
  5. Arterial switch

Exclusion Criteria:

• Pulmonary artery or vein abnormalities not being addressed surgically
• Preoperative requirement for mechanical ventilation or intravenous inotrope support
• Any condition that might interfere with study objectives, as determined by the investigator
• Pregnant

Contacts and Locations

Locations

United States, Tennessee

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

Asklepion Pharmaceuticals, LLC

Vanderbilt University

Investigators

• Principal Investigator: Fredrick E. Barr, MD, MSCI; Vanderbilt University Medical Center

More Information

• Responsible Party: Asklepion Pharmaceuticals, LLC
• ClinicalTrials.gov Identifier: NCT00335244
• Other Study ID Numbers: 409; R01HL073317-01 ( U.S. NIH Grant/Contract ); IRB# 060197
• First Posted: June 9, 2006
• Last Update Posted: February 2, 2015
• Last Verified: January 2015

Additional relevant MeSH terms:

Hypertension, Pulmonary; Heart Defects, Congenital; Congenital Abnormalities; Hypertension; Vascular Diseases; Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases; Cardiovascular Abnormalities; Heart Diseases